UK News Oxford’s 90% vaccine finding was ‘only in younger age groups’

17:10  26 november  2020
17:10  26 november  2020 Source:   msn.com

Can shark liver, tree bark and sand help deliver the Covid vaccine?

  Can shark liver, tree bark and sand help deliver the Covid vaccine? The jabs will have to be manufactured at an unprecedented scale and pace, transported to every corner of the globe and, ultimately, injected into arm after arm after arm. © Provided by Daily Mail But the race is only partially run. Questions remain. For example, with the Pfizer jab it¿s not clear exactly what is meant by it being ¿90 per cent effective¿.

The Oxford University and AstraZeneca vaccine trials reached 90 % efficacy by accident thanks to the “serendipity” of an error that led to some participants receiving half-doses, it has emerged. On Monday scientists revealed that the Oxford vaccine had an overall efficacy of 70%, but could be around 90

The coronavirus vaccine developed by the University of Oxford is highly effective at stopping Prof Pollard said the finding was "intriguing" and would mean "we would have a lot more doses to In some cases your question will be published, displaying your name, age and location as you provide it

The dose of AstraZeneca and Oxford University’s Covid-19 vaccine that was shown to be 90% effective was only tested in people aged 55 and under, according to a US official.

Moncef Slaoui, the scientific head of the US’s Operation Warp Speed – the programme to supply America with vaccines – told US reporters that the half-dose regime, which was discovered by accident, was only given to younger age groups.

Scientists across the globe are hoping to find vaccines that work in older people, who are most at risk from Covid-19.

Oxford’s overall efficacy from two different dosing regimes in a phase three trial was announced last week at a combined figure of 70%.

Pfizer vaccine is 95% effective and works in older people, new data shows

  Pfizer vaccine is 95% effective and works in older people, new data shows Of 170 Covid-19 cases in the new analysis, 162 were observed in the placebo group versus eight in the vaccine group. A good immune response was “consistent across age, gender, race and ethnicity demographics”, Pfizer said.Of those taking part in the trial, 42% were from diverse ethnic backgrounds and 41% were aged between 56 and 85.Older age groups are most at risk of serious illness from Covid-19.In the new analysis, there were 10 severe cases of Covid-19, with nine in the placebo group and one in the vaccine group.

Younger people tend to have stronger responses to some kinds of vaccines . The British-Swedish multinational is one of many vaccine producers racing to offer their products to nations worldwide. “I don't believe that the FDA will look positively at any trial where the dose, or the age cohorts, or any

The Oxford technology is more established so the vaccine is easier to mass produce cheaply and If Oxford ' s vaccine enters public domain the recipe can be shared worldwide so countries can Which incidentally, is why antivaxxers are such a group of numpties- its not just their own health, they're

A half dose followed by a full dose was found to be 90% effective according to a subset of data, but efficacy was 62% for people given two full doses.

diagram, text: (PA Graphics) © Provided by PA Media (PA Graphics)

Results from an earlier phase two study of the vaccine published in The Lancet medical journal showed the vaccine produced a strong response in all age groups.

Professor Andrew Pollard, director of the Oxford Vaccine Group, told reporters at a UK-based press briefing last week that the 90% effectiveness finding had already met the “necessary statistical evidence as required by regulators”.

He said further evidence will probably be available next month but it is “a highly significant result even with the numbers that we have”.

The 90% efficacy was based on a dosing regime given to 2,741 people.

Differing vaccine priority list for UK vs France

  Differing vaccine priority list for UK vs France Based on guidance from the Joint Committee on Vaccination and Immunisation (JCVI), the first people in the UK to get any new vaccine will be elderly care homes and those who work in them. They will be followed by people over the age of 80 and NHS staff. All other age groups will then receive the jab in stages, with people under 50 the last to get it. However the UK strategy makes no mention of other workers who have close contact with the general public, including those in the hospitality sectors, teachers and cab drivers.

Oxford University announced on Monday that a coronavirus vaccine is found to offer 70 On 23 November, Oxford University announced results of its trial which found the vaccine stops 70 per It said: “This advice assumes availability of a vaccine which is safe and effective in all age groups and

Dosing ERROR by researchers in the AstraZeneca- Oxford University vaccine trial boosted its success rate to 90 %, firm’s vice-president reveals. Study results published yesterday showed that Oxford ' s vaccine appeared to be up to 90 per cent effective in people who received the vaccine as a half-dose

The other regime (two doses) involved 8,895 people.

Neither AstraZeneca nor Oxford disclosed at the briefing that the 90% figure was based on adults aged 55 and under.

It comes as some US scientists have questioned a lack of detail in the results put out last week by AstraZeneca and Oxford.

The New York Times reported that AstraZeneca’s Menelas Pangalos has defended the company’s handling of testing and its public disclosures.

He said the error in the dosage was made by a contractor, and that, once it was discovered, regulators were immediately notified and agreed to continued testing of the vaccine in different doses.

Asked why AstraZeneca had not shared the information with the public, he said: “I think the best way of reflecting the results is in a peer-reviewed scientific journal, not in a newspaper.”

Vaccine volunteers describe special feeling as Oxford reports positive data

  Vaccine volunteers describe special feeling as Oxford reports positive data Sarah Hurst and Jack Sommers paid tribute to the scientists and researchers involved in the AstraZeneca and Oxford University trial.Sarah Hurst, 47, took part in the AstraZeneca and Oxford University research, receiving two jabs of either the experimental vaccine or a placebo.

The Oxford vaccine is a genetically engineered common cold virus that used to infect chimpanzees. Oxford ' s trials found that the jab has a nine in ten chance of working when administered as a half dose first and then a full dose a month later. Andrew Pollard is the director of the Oxford vaccine group .

Oxford University' s coronavirus vaccine triggers a 'robust' immune response in the elderly, a study has shown. It suggests the group at highest risk of Previous research had proven the jab, currently the global frontrunner, could prompt an immune response in younger people, who are less affected by

Some experts have also raised questions about the use of two differently designed clinical trials in Britain and Brazil, and pooling analysis from both.

They also say it is unclear how many coronavirus cases were found in each group of the trial.

John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, told the New York Times: “The press release raised more questions than it answered.”

In an interview with the New York Times, Mr Pangalos said the half-dose finding “could end up being quite a useful mistake”.

He added: “It wasn’t putting anyone in danger. It was a dosing error. Everyone was moving very fast.

“We corrected the mistake and continued on with the study, with no changes to the study, and agreed with the regulator to include those patients in the analysis of the study as well.”

He added: “What is there to disclose? It actually doesn’t matter whether it was done on purpose or not.”

Mr Pangalos said the company is planning a global trial with thousands of people to compare the two dosing regimes.

The Oxford vaccine is inexpensive at only £2 to £3 per dose and can be much more easily stored than vaccines from Pfizer/BioNTech and Moderna, which require very cold temperatures.

The jab is currently being assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK.

In an interview with the PA news agency last week, Tom Keith-Roach, president of AstraZeneca UK, said the UK could receive 19 million doses of the jab by the end of the year if it is approved.

On the 90% efficacy result, he said: “We’ve proved significance in all of those subgroups to a p value of 0.0001.

“So these are highly statistically significant efficacy results in all subgroups. And so I think the regulators will look at it on that basis.”

A spokesman for AstraZeneca told PA on Thursday: “The studies were conducted to the highest standards.

“An independent Data and Safety Monitoring Board (DSMB) safety monitoring committee oversees the studies to ensure safety and quality.

Oxford AstraZeneca vaccine results: Why we shouldn’t be concerned about the Covid jab’s 90% effectiveness

  Oxford AstraZeneca vaccine results: Why we shouldn’t be concerned about the Covid jab’s 90% effectiveness There is concern the 90% effectiveness rate only applies to adults aged 55 and youngerEarlier this week, Oxford University and pharmaceutical company AstraZeneca revealed that its jab was at least 70.4 per cent effective in preventing people from getting Covid-19, according to data from interim phase three trials in the UK and Brazil.

“The DSMB determined that the analysis met its primary endpoint showing protection from Covid-19 occurring 14 days or more after receiving two doses of the vaccine.

“Following established clinical trial standards, the data will be published in a peer-reviewed journal in due course.

“All results were statistically significant with a p value of less than or equal to 0.0001.

“More data will continue to accumulate and additional analysis will be conducted refining the efficacy reading and establishing the duration of protection.”

Peter Openshaw, professor of experimental medicine at Imperial College London, said: “We have to wait for the full data and to see how the regulators view the results of the phase three trials.

“The US and European regulators might possibly take a different view.

“All we have to go on is a limited data release.”

Paul Hunter, professor of medicine at the University of East Anglia (UEA), told PA: “Given that many vaccines are less effective in older people, we have to be even more cautious about taking this 90% efficacy at face value, at least for older people.”

Oxford University said it would not comment ahead of the data appearing in a peer-reviewed publication.

But in a statement to PA it said: “During the phase three trials, our UK study used two dose levels.

“The initial dose selection, which was agreed with regulators, was based on the same measurement of the concentration (using spectrophotometry) used in the phase one study, but, as a result of a difference in the manufacturing process for the later study, this method was subsequently shown to overestimate the dose on the new batches of vaccine, resulting in a half dose of the vaccine being administered as the first dose.

“We have different ways of measuring the concentration of the vaccine and, when it was apparent that a lower dose was used, we discussed this with the regulator, and agreed a plan to test both the lower dose/higher dose and higher dose/higher dose, allowing us to include both approaches in the phase three trial.

“The methods for measuring the concentration are now established and we can ensure that all batches of vaccine are now equivalent.”

The Prime Minister’s official spokesman said: “It’s for the independent MHRA to look at all the data provided by the Oxford-AstraZeneca team.

“They are an independent agency who will study the data and it is for them to make a judgment on the safety and effectiveness.”

Corona vaccine from AstraZeneca and Oxford University: The pharmaceutical company admits errors in the studies - the timely emergency approval of the vaccine in the EU is now probably in question .
On Monday of this week everything initially looked pretty good. But only for a brief moment. The company AstraZeneca, which is developing a vaccine against Covid-19 with Oxford University, reported to that their vaccine was 90 percent effective in a study group. Less than four days later, the chaos is perfect. AstraZeneca has now admitted errors - among other things, that the wrong dosage was used in said study group, which was found to be highly effective.

usr: 0
This is interesting!